Vital Signsby BridgeheadAll journalists

01  Journalist · FierceBiotech · Respiratory (asthma/COPD)

James Waldron: no photograph is held, so their initials are shown instead.
Journalist

James Waldron

FierceBiotech and 1 other title

Articles read per month · health & social care
Mar 2026AprMayJuneJulyAugSeptOctNovto date

Bars cover the last twelve months and show relative volume.

Bylines read on 3 topics since 12 Mar 2026 · latest 30 Sept 2026

Files to · bar length shows relative volume
  • FierceBiotech
  • Fierce Biotech

This counts only pieces our coverage scan read on the topics Vital Signs tracks, not their full output.

02  Writes on · 3 of 29 topics

Open the topic

James Waldron: key facts

Main title
FierceBiotech
Covers
Respiratory (asthma/COPD), Rare diseases, Diabetes
Press coverage
Bylined in the pressby our coverage scan, not their full output
Most recently read
30 Sept 2026
First read
12 Mar 2026

03  Beat

What James Waldron covers

How we found the articles by James Waldron we read: we searched news for these terms, by topic. Terms for 3 topics

Respiratory (asthma/COPD)

  • asthma
  • COPD
  • respiratory disease
  • lung cancer screening
  • pulmonary

Also searched with “asthma” in each of 8 national papers, and in the Guardian by editor tag, and in trade press by category. Every term for Respiratory (asthma/COPD)

Rare diseases

  • rare disease
  • rare conditions
  • orphan drugs
  • genetic disorder
  • cystic fibrosis
  • motor neurone disease
  • muscular dystrophy
  • Huntington

Also searched with “rare disease” in each of 8 national papers. Every term for Rare diseases

Diabetes

  • diabetes
  • type 1 diabetes
  • type 2 diabetes
  • insulin
  • diabetic
  • diabetes prevention

Also searched with “diabetes” in each of 8 national papers, and in the Guardian by editor tag, and in trade press by category. Every term for Diabetes

04  Who they quote

Who James Waldron calls

Voices credited in their pieces. A reporter who has called someone before is likely to call them again.

  1. Houman Ashrafian, Ph.D.Sector leader
  2. Francis Burrows, Ph.D.Sector leader

05  The record

Recent articles

  1. 30 Sept 2026
    Connect’s Dupixent rival reduces COPD attacks by 85%, but misses a secondary goal

    Fierce BiotechRespiratory (asthma/COPD)

  2. 16 Sept 2026
    Sionna lays off 46% of workforce in strategic shift after cystic fibrosis trial fail

    FierceBiotechRare diseases

  3. 10 Sept 2026
    Kura creates Lilly-backed spinout armed with $50M to advance next-gen diabetes therapy

    FierceBiotechDiabetes

  4. 7 Apr 2026
    Sanofi’s bispecific scores double respiratory phase 2 wins, but flunks eczema study

    FierceBiotechRespiratory (asthma/COPD)

  5. 12 Mar 2026
    Small molecules are 'resurgent' in orphan drug R&D: Evaluate

    FierceBiotechRare diseases

Bylines and quoted sources are read automatically from UK coverage of the topics Vital Signs tracks, so this page reflects what our scan has read rather than a complete record. Where a biography appears, it is published by the outlet itself about its own correspondent, and linked above. Photographs come from the outlet’s own byline or author page, or from the journalist’s LinkedIn profile, and each is credited under the picture. Social accounts are not held: asserting an unverified one would attach a real person to an account that might not be theirs. See the methodology, or email contact@bridgeheadcommunications.com to correct anything on it.